• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服霉酚酸酯后肾移植受者霉酚酸的群体药代动力学分析。

Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.

作者信息

Shum B, Duffull S B, Taylor P J, Tett S E

机构信息

School of Pharmacy, University of Queensland, Brisbane, Australia.

出版信息

Br J Clin Pharmacol. 2003 Aug;56(2):188-97. doi: 10.1046/j.1365-2125.2003.01863.x.

DOI:10.1046/j.1365-2125.2003.01863.x
PMID:12895192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1884287/
Abstract

AIM

To develop a population pharmacokinetic model for mycophenolic acid in adult kidney transplant recipients, quantifying average population pharmacokinetic parameter values, and between- and within-subject variability and to evaluate the influence of covariates on the pharmacokinetic variability.

METHODS

Pharmacokinetic data for mycophenolic acid and covariate information were previously available from 22 patients who underwent kidney transplantation at the Princess Alexandra Hospital. All patients received mycophenolate mofetil 1 g orally twice daily. A total of 557 concentration-time points were available. Data were analysed using the first-order method in NONMEM (version 5 level 1.1) using the G77 FORTRAN compiler.

RESULTS

The best base model was a two-compartment model with a lag time (apparent oral clearance was 27 l h(-1), and apparent volume of the central compartment 98 l). There was visual evidence of complex absorption and time-dependent clearance processes, but they could not be successfully modelled in this study. Weight was investigated as a covariate, but no significant relationship was determined.

CONCLUSIONS

The complexity in determining the pharmacokinetics of mycophenolic acid is currently underestimated. More complex pharmacokinetic models, though not supported by the limited data collected for this study, may prove useful in the future. The large between-subject and between-occasion variability and the possibility of nonlinear processes associated with the pharmacokinetics of mycophenolic acid raise questions about the value of the use of therapeutic monitoring and limited sampling strategies.

摘要

目的

建立成年肾移植受者霉酚酸的群体药代动力学模型,量化群体药代动力学参数的平均数值、个体间和个体内变异性,并评估协变量对药代动力学变异性的影响。

方法

先前已获得亚历山德拉公主医院22例接受肾移植患者的霉酚酸药代动力学数据和协变量信息。所有患者均口服霉酚酸酯,每日2次,每次1 g。共获得557个浓度-时间点。使用G77 FORTRAN编译器,采用NONMEM(版本5 1.1级)中的一级方法对数据进行分析。

结果

最佳基础模型为具有滞后时间的二室模型(表观口服清除率为27 l·h-1,中央室表观容积为98 l)。有直观证据表明存在复杂的吸收和时间依赖性清除过程,但在本研究中无法成功建模。研究了体重作为协变量,但未确定显著关系。

结论

目前对霉酚酸药代动力学测定的复杂性估计不足。更复杂的药代动力学模型虽然未得到本研究收集的有限数据的支持,但未来可能会证明有用。霉酚酸药代动力学相关的个体间和个体内较大变异性以及非线性过程的可能性,引发了关于治疗药物监测和有限采样策略价值的疑问。

相似文献

1
Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil.口服霉酚酸酯后肾移植受者霉酚酸的群体药代动力学分析。
Br J Clin Pharmacol. 2003 Aug;56(2):188-97. doi: 10.1046/j.1365-2125.2003.01863.x.
2
Population pharmacokinetics of mycophenolic acid in renal transplant recipients.肾移植受者中霉酚酸的群体药代动力学。
Clin Pharmacokinet. 2005;44(10):1083-96. doi: 10.2165/00003088-200544100-00006.
3
Population Pharmacokinetic Analysis of Immediate-Release Oral Tacrolimus Co-administered with Mycophenolate Mofetil in Corticosteroid-Free Adult Kidney Transplant Recipients.在无皮质类固醇的成年肾移植受者中,与霉酚酸酯联合使用的速释口服他克莫司的群体药代动力学分析。
Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):409-422. doi: 10.1007/s13318-018-0525-3.
4
Clinical pharmacokinetics of mycophenolate mofetil.霉酚酸酯的临床药代动力学。
Clin Pharmacokinet. 1998 Jun;34(6):429-55. doi: 10.2165/00003088-199834060-00002.
5
Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients.在初治的儿科肾移植患者中,霉酚酸酯给药后的霉酚酸群体药代动力学和药物遗传学。
J Clin Pharmacol. 2010 Nov;50(11):1280-91. doi: 10.1177/0091270009357429. Epub 2010 Feb 10.
6
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.中国成年肾移植受者中霉酚酸浓度的群体药代动力学及贝叶斯估计
Acta Pharmacol Sin. 2017 Nov;38(11):1566-1579. doi: 10.1038/aps.2017.115. Epub 2017 Aug 24.
7
Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction.成人慢性移植物功能障碍肾移植患者麦考酚酸的群体药代动力学分析。
Ther Drug Monit. 2010 Aug;32(4):427-32. doi: 10.1097/FTD.0b013e3181e6b54d.
8
Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients.合并使用托法替尼(CP-690,550)或他克莫司的成人肾移植受者麦考酚酸群体药代动力学分析。
Ther Drug Monit. 2010 Dec;32(6):778-81. doi: 10.1097/FTD.0b013e3181f361c9.
9
A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil.双吸收相模型能够充分描述口服吗替麦考酚酯的初治肾移植受者体内的霉酚酸血浆浓度曲线。
Clin Pharmacokinet. 2005;44(8):837-47. doi: 10.2165/00003088-200544080-00005.
10
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.解释霉酚酸暴露量的变异性以优化霉酚酸酯剂量:肾移植受者中霉酚酸的群体药代动力学荟萃分析
J Am Soc Nephrol. 2006 Mar;17(3):871-80. doi: 10.1681/ASN.2005101070. Epub 2006 Feb 1.

引用本文的文献

1
Population pharmacokinetic analysis identifies an absorption process model for mycophenolic acid in patients with renal transplant.群体药代动力学分析确定了肾移植患者中霉酚酸的吸收过程模型。
Clin Transl Sci. 2024 Dec;17(12):e70097. doi: 10.1111/cts.70097.
2
Population pharmacokinetics and limited sampling strategy for therapeutic drug monitoring of mycophenolate mofetil in Japanese patients with lupus nephritis.日本狼疮性肾炎患者霉酚酸酯治疗药物监测的群体药代动力学及有限采样策略
J Pharm Health Care Sci. 2023 Jan 9;9(1):1. doi: 10.1186/s40780-022-00271-w.
3
Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.应用群体分析阐明生物等效性研究中的吸收机制和变异性。
Pharm Res. 2021 Dec;38(12):2047-2063. doi: 10.1007/s11095-021-03136-3. Epub 2021 Dec 21.
4
Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients.他克莫司合用霉酚酸在皮质类固醇-free 成年肾移植患者群体药代动力学。
Clin Pharmacokinet. 2019 Nov;58(11):1483-1495. doi: 10.1007/s40262-019-00771-3.
5
Mycophenolic Acid and Its Metabolites in Kidney Transplant Recipients: A Semimechanistic Enterohepatic Circulation Model to Improve Estimating Exposure.肾移植受者中的霉酚酸及其代谢产物:一种用于改善暴露量估计的半机制性肠肝循环模型
J Clin Pharmacol. 2018 May;58(5):628-639. doi: 10.1002/jcph.1064. Epub 2018 Jan 12.
6
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients.中国成年肾移植受者中霉酚酸浓度的群体药代动力学及贝叶斯估计
Acta Pharmacol Sin. 2017 Nov;38(11):1566-1579. doi: 10.1038/aps.2017.115. Epub 2017 Aug 24.
7
Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients.汉族肾移植受者中肠溶型麦考酚钠剂量与麦考酚酸暴露之间的非线性关系。
Acta Pharm Sin B. 2017 May;7(3):347-352. doi: 10.1016/j.apsb.2016.11.003. Epub 2016 Dec 10.
8
Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.异基因造血细胞移植中免疫抑制剂的药代动力学、药效学和药物基因组学:第二部分。
Clin Pharmacokinet. 2016 May;55(5):551-93. doi: 10.1007/s40262-015-0340-9.
9
Clinical mycophenolic acid monitoring in liver transplant recipients.肝移植受者的临床霉酚酸监测
World J Gastroenterol. 2014 Aug 21;20(31):10715-28. doi: 10.3748/wjg.v20.i31.10715.
10
How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?在估计自身免疫性疾病患者霉酚酸暴露量方面,有限采样策略的准确性和精密度如何?
Clin Pharmacokinet. 2014 Mar;53(3):227-245. doi: 10.1007/s40262-013-0124-z.

本文引用的文献

1
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation.糖皮质激素会干扰肾移植中霉酚酸酯的生物利用度。
Kidney Int. 2002 Sep;62(3):1060-7. doi: 10.1046/j.1523-1755.2002.00531.x.
2
Monitoring of mycophenolic acid in clinical transplantation.临床移植中霉酚酸的监测
Ther Drug Monit. 2002 Feb;24(1):68-73. doi: 10.1097/00007691-200202000-00012.
3
Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion.霉酚酸治疗药物监测的当前问题:圆桌讨论报告
Ther Drug Monit. 2001 Aug;23(4):305-15. doi: 10.1097/00007691-200108000-00001.
4
Assessment of actual significance levels for covariate effects in NONMEM.评估NONMEM中协变量效应的实际显著性水平。
J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):231-52. doi: 10.1023/a:1011527125570.
5
Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.低剂量霉酚酸酯与他克莫司联合用于肾移植时高效安全使用的药代动力学基础。
Clin Chem. 2001;47(7):1241-8.
6
Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.他克莫司与环孢素对霉酚酸药代动力学影响的比较。
Ther Drug Monit. 2001 Apr;23(2):119-28. doi: 10.1097/00007691-200104000-00005.
7
A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients.肾移植受者中霉酚酸和环孢素浓度与急性排斥反应的回顾性分析。
Clin Biochem. 2001 Feb;34(1):77-81. doi: 10.1016/s0009-9120(00)00196-x.
8
Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.药代动力学、药效学及转归研究作为肾移植和心脏移植患者霉酚酸治疗药物监测的基础
Clin Biochem. 2001 Feb;34(1):17-22. doi: 10.1016/s0009-9120(00)00184-3.
9
Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients.评估有限采样策略用于估计成年肾移植患者血浆浓度-时间曲线下12小时霉酚酸面积的情况。
Ther Drug Monit. 2000 Oct;22(5):549-54. doi: 10.1097/00007691-200010000-00008.
10
The use of mycophenolate mofetil in transplant recipients.霉酚酸酯在移植受者中的应用。
Immunopharmacology. 2000 May;47(2-3):215-45. doi: 10.1016/s0162-3109(00)00190-9.